Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Journal of Cancer Research and Clinical Oncology
Erschienen in: Journal of Cancer Research and Clinical Oncology 7/2011

01.07.2011 | Original Paper

18F-FDG PET or PET-CT to evaluate prognosis for head and neck cancer: a meta-analysis

verfasst von: Peng Xie, Minghuan Li, Hanxi Zhao, Xindong Sun, Zheng Fu, Jinming Yu

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 7/2011

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The purpose of this meta-analysis was to evaluate the prognostic value of standard uptake value (SUV) from serial Fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) in patients with head and neck cancer.

Methods

We searched for articles limited to head and neck cancer, dealt with the impact of SUV on survival and published in English. The endpoints were disease-free survival (DFS), overall survival (OS), and local control (LC). Two reviewers extracted data independently.

Results

Thirty-five studies were identified; of which, 26 studies involving 1,415 patients met the inclusion criteria. Pooled survival data suggested better DFS, OS, and LC in patients with low SUV of pre-treatment, and the odds ratio (OR) was 0.23, 0.24, and 0.27, respectively. Patients having tumors with low SUV of post-treatment also had significantly better DFS (OR = 0.17) and OS (OR = 0.28) than those with high SUV.

Conclusions

The present meta-analysis showed that 18F-FDG uptake, as measured by the SUV before treatment and metabolic response after treatment, are valuable for predicting long-term survival in head and neck cancer. High 18F-FDG uptake may be useful for identifying patients requiring more aggressive treatment.
Literatur
Allal AS, Dulguerov P, Allaoua M et al (2002) Standardized uptake value of 2-[18F] fluoro-2-deoxy-d-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy. J Clin Oncol 20(5):1398–1404PubMedCrossRef
Allal AS, Slosman DO, Kebdani T et al (2004) Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-[18F]fluoro-2-deoxy-d-glucose. Int J Radiat Oncol Biol Phys 59(5):1295–1300PubMedCrossRef
Bernier J, Domenge C, Ozsahin M et al (2004) Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350(19):1945–1952PubMedCrossRef
Bonner JA, Harari PM, Giralt J et al (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354(6):567–578PubMedCrossRef
Brun E, Kjellén E, Tennvall J et al (2002) FDG PET studies during treatment: prediction of therapy outcome in head and neck squamous cell carcinoma. Head Neck 24(2):127–135PubMedCrossRef
Byun BH, Na II, Cheon GJ et al (2008) Clinical significance of 18F-FDG uptake by primary sites in patients with diffuse large B cell lymphoma in the head and neck: a pilot study. Ann Nucl Med 22(8):645–651PubMedCrossRef
Chan SC, Chang JT, Wang HM et al (2009) Prediction for distant failure in patients with stage M0 nasopharyngeal carcinoma: the role of standardized uptake value. Oral Oncol 45:52–58PubMedCrossRef
Chung MK, Jeong HS, Park SG et al (2009) Metabolic tumor volume of [18F]-fluorodeoxyglucose positron emission tomography/computed tomography predicts short-term outcome to radiotherapy with or without chemotherapy in pharyngeal cancer. Clin Cancer Res 15(18):5861–5868PubMedCrossRef
Cicone F, Loose D, Deron P et al (2008) Prognostic value of FDG uptake by the bone marrow in squamous cell carcinoma of the head and neck. Nucl Med Commun 29(5):431–435PubMedCrossRef
Cohen EEW, Lingen MW, Vokes EE (2004) The expanding role of systemic therapy in head and neck cancer. J Clin Oncol 22:1743–1752PubMedCrossRef
Cunningham D, Allum WH, Stenning SP et al (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 80:11–20CrossRef
Döbert N, Kovács AF, Menzel C et al (2005) The prognostic value of FDG PET in head and neck cancer. Correlation with histopathology. Q J Nucl Med Mol Imaging 49(3):253–257PubMed
Garden AS, Asper JA, Morrison WH et al (2004) Is concurrent chemoradiation the treatment of choice for all patients with Stage III or IV head and neck carcinoma? Cancer 100:1171–1178PubMedCrossRef
Greven KM, Williams DW 3rd, Keyes JW Jr et al (1994) Positron emission tomography of patients with head and neck carcinoma before and after high dose irradiation. Cancer 74(4):1355–1359PubMedCrossRef
Greven KM, Williams DW 3rd, McGuirt WF Sr et al (2001) Serial positron emission tomography scans following radiation therapy of patients with head and neck cancer. Head Neck 23(11):942–946PubMedCrossRef
Halfpenny W, Hain SF, Biassoni L et al (2002) FDG-PET. A possible prognostic factor in head and neck cancer. Br J Cancer 86(4):512–516PubMedCrossRef
Hoshikawa H, Mitani T, Nishiyama Y et al (2009) Evaluation of the therapeutic effects and recurrence for head and neck cancer after chemoradiotherapy by FDG-PET. Auris Nasus Larynx 36(2):192–198PubMedCrossRef
Juweid ME, Stroobants S, Hoekstra OS et al (2007) Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 25:571–578PubMedCrossRef
Kao CH, Shiau YC, Shen YY et al (2002) Detection of recurrent or persistent nasopharyngeal carcinomas after radiotherapy with technetium-99 m methoxyisobutylisonitrile single photon emission computed tomography and computed tomography: comparison with 18-fluoro-2-deoxyglucose positron emission tomography. Cancer 94:1981–1986PubMedCrossRef
Kim SY, Roh JL, Kim JS et al (2008) Utility of FDG PET in patients with squamous cell carcinomas of the oral cavity. Eur J Surg Oncol 34(2):208–215PubMed
Krishna SM, James S, Balaram P (2006) Expression of VEGF as prognosticator in primary nasopharyngeal cancer and its relation to EBV status. Virus Res 115:85–90PubMedCrossRef
Kunkel M, Reichert TE, Benz P et al (2003a) Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma. Cancer 97(4):1015–1024PubMedCrossRef
Kunkel M, Förster GJ, Reichert TE et al (2003b) Radiation response non-invasively imaged by [18F]FDG-PET predicts local tumor control and survival in advanced oral squamous cell carcinoma. Oral Oncol 39(2):170–177PubMedCrossRef
Kunkel M, Helisch A, Reichert TE et al (2006) Clinical and prognostic value of [(18)F]FDG-PET for surveillance of oral squamous cell carcinoma after surgical salvage therapy. Oral Oncol 42(3):297–305PubMedCrossRef
La TH, Filion EJ, Turnbull BB et al (2009) Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer. Int J Radiat Oncol Biol Phys 74(5):1335–1341PubMedCrossRef
Lee SW, Cho KJ, Park JH et al (2005) Expressions of Ku70 and DNA-PKcs as prognostic indicators of local control in nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 62:1451–1457PubMedCrossRef
Lee P, Weerasuriya DK, Lavori PW et al (2007) Metabolic tumor burden predicts for disease progression and death in lung cancer. Int J Radiat Oncol Biol Phys 69:328–333PubMedCrossRef
Lee SW, Nam SY, Im KC et al (2008) Prediction of prognosis using standardized uptake value of 2–18F- fluoro-2-deoxy-d-glucose positron emission tomography for nasopharyngeal carcinomas. Radiother Oncol 87:211–216PubMedCrossRef
Liao CT, Chang JT, Wang HM et al (2009) Pretreatment primary tumor SUVmax measured by FDG-PET and pathologic tumor depth predict for poor outcomes in patients with oral cavity squamous cell carcinoma and pathologically positive lymph nodes. Int J Radiat Oncol Biol Phys 73(3):764–771PubMedCrossRef
Lin C, Itti E, Haioun C et al (2007) Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med 48:1626–1632PubMedCrossRef
Linecker A, Kermer C, Sulzbacher I et al (2008) Uptake of (18)F-FLT and (18)F-FDG in primary head and neck cancer correlates with survival. Nuklearmedizin 47(2):80–85PubMed
Lordick F, Ott K, Krause BJ et al (2007) PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol 8:797–805PubMedCrossRef
Machtay M, Natwa M, Andrel J et al (2009) Pretreatment FDG-PET standardized uptake value as a prognostic factor for outcome in head and neck cancer. Head Neck 31(2):195–201PubMedCrossRef
Minn H, Lapela M, Klemi PJ et al (1997) Prediction of survival with fluorine-18-fluoro-deoxyglucose and PET in head and neck cancer. J Nucl Med 38(12):1907–1911PubMed
Nakao K, Mochiki M, Nibu K et al (2006) Analysis of prognostic factors of nasopharyngeal carcinoma: impact of in situ hybridization for Epstein–Barr virus encoded small RNA1. Otolaryngol Head Neck Surg 134:639–645PubMedCrossRef
Okada J, Oonishi H, Yoshikawa K et al (1994) FDG-PET for predicting the prognosis of malignant lymphoma. Ann Nucl Med 8(3):187–191PubMedCrossRef
Rege S, Safa AA, Chaiken L et al (2000) Positron emission tomography: an independent indicator of radiocurability in head and neck carcinomas. Am J Clin Oncol 23(2):164–169PubMed
Roh JL, Ryu CH, Choi SH et al (2007) Clinical utility of 18F-FDG PET for patients with salivary gland malignancies. J Nucl Med 48(2):240–246PubMed
Sanghera B, Wong WL, Lodge MA et al (2005) Potential novel application of dual time point SUV measurements as a predictor of survival in head and neck cancer. Nucl Med Commun 26(10):861–867PubMedCrossRef
Sasaki R, Komaki R, Macapinlac H et al (2005) [18F]fluorodeoxy-glucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol 23:1136–1143PubMedCrossRef
Schönberger J, Rüschoff J, Grimm D et al (2002) Glucose transporter 1 gene expression is related to thyroid neoplasms with an unfavorable prognosis: an immunohistochemical study. Thyroid 12(9):747–754PubMedCrossRef
Schwartz DL, Rajendran J, Yueh B et al (2004) FDG-PET prediction of head and neck squamous cell cancer outcomes. Arch Otolaryngol Head Neck Surg 130(12):1361–1367PubMedCrossRef
Schwarz JK, Siegel BA, Dehdashti F et al (2008) Tumor response and survival predicted by post-therapy FDG-PET/CT in anal cancer. Int J Radiat Oncol Biol Phys 71:180–186PubMedCrossRef
Seol YM, Kwon BR, Song MK et al (2010) Measurement of tumor volume by PET to evaluate prognosis in patients with head and neck cancer treated by chemo-radiation therapy. Acta Oncol 49(2):201–208PubMedCrossRef
Spiro SG, Buscombe J, Cook G et al (2008) Ensuring the right PET scan for the right patient. Lung Cancer 59:48–56PubMedCrossRef
Suh C, Kang YK, Roh JL et al (2008) Prognostic value of tumor 18F-FDG uptake in patients with untreated extranodal natural killer/T-cell lymphomas of the head and neck. J Nucl Med 49(11):1783–1789PubMedCrossRef
Thorwarth D, Eschmann SM, Holzner F et al (2006) Combined uptake of [18F]FDG and [18F]FMISO correlates with radiation therapy outcome in head-and-neck cancer patients. Radiother Oncol 80(2):151–156PubMedCrossRef
Torizuka T, Tanizaki Y, Kanno T et al (2009) Prognostic value of 18F-FDG PET in patients with head and neck squamous cell cancer. AJR Am J Roentgenol 192(4):W156–W160PubMedCrossRef
van Tinteren H, Hoekstra OS, Smit EF et al (2002) Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet 359:1388–1393PubMedCrossRef
Wieder HA, Beer AJ, Lordick F et al (2005) Comparison of changes in tumor metabolic activity and tumor size during chemotherapy of adenocarcinomas of the esophagogastric junction. J Nucl Med 46:2029–2034PubMed
Xie P, Yue JB, Fu Z et al (2010a) Prognostic value of 18F-FDG PET/CT before and after radiotherapy for locally advanced nasopharyngeal carcinoma. Ann Oncol 21(5):1078–1082PubMedCrossRef
Xie P, Yue JB, Zhao HX et al (2010b) Prognostic value of 18F-FDG PET-CT metabolic index for nasopharyngeal carcinoma. J Cancer Res Clin Oncol 136(6):883–889PubMedCrossRef
Yao M, Smith RB, Hoffman HT et al (2009) Clinical significance of postradiotherapy [18F]-fluorodeoxyglucose positron emission tomography imaging in management of head-and-neck cancer-a long-term outcome report. Int J Radiat Oncol Biol Phys 74(1):9–14PubMedCrossRef
Yen RF, Hong RL, Tzen KY et al (2005) Whole-body 18F-FDG PET in recurrent or metastatic nasopharyngeal carcinoma. J Nucl Med 46(5):770–774PubMed
Yen TC, Lin CY, Wang HM et al (2006) 18F-FDG-PET for evaluation of the response to concurrent chemoradiation therapy with intensity-modulated radiation technique for Stage T4 nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 65(5):1307–1314PubMedCrossRef
Metadaten
Titel
18F-FDG PET or PET-CT to evaluate prognosis for head and neck cancer: a meta-analysis
verfasst von
Peng Xie
Minghuan Li
Hanxi Zhao
Xindong Sun
Zheng Fu
Jinming Yu
Publikationsdatum
01.07.2011
Verlag
Springer-Verlag
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 7/2011
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-010-0972-y

Weitere Artikel der Ausgabe 7/2011

Journal of Cancer Research and Clinical Oncology 7/2011 Zur Ausgabe

Original Paper

Treatment of advanced non-small-cell lung cancer with Chinese herbal medicine by stages combined with chemotherapy

Original Paper

Clinical significance of progesterone receptor and HER2 status in estrogen receptor-positive, operable breast cancer with adjuvant tamoxifen

Original Paper

Expression of chemokine receptor CCR5 correlates with the presence of hepatic molecular metastases in K-ras positive human colorectal cancer

Review

The influence of family history and histological stratification on breast cancer risk in women with benign breast disease: a meta-analysis

Original Paper

Intra-hepatic cholangiocarcinoma—frequency and demographic patterns: thirty-year data from the M.D. Anderson Cancer Center

Original Paper

IL-8-251A>T polymorphism is associated with breast cancer risk: a meta-analysis

Neu im Fachgebiet Onkologie

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise